when the bulk drug vitamins going into the manufacture of multivitamin medicines are out of price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The Kelkar Committee had recommended that all vitamins, only when used in combinations in formulations should come under Category 11 of price control. Keeping this recommendation in view, all vitamins as bulk drugs have been exempted from price control.

(b) The prices of vitamins when used in combinations in formulations will be controlled under the provisions of DPCO, 1987.

Increasing the drug prices by Drug Companies

2514. SHRI BHUBANESWAR KALITA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that a number of companies have increased the prices of their formulations without submitting the break-up on form No. 4;

(b) whether it is a fact that such instances have have come to the notice of his Ministry;

(c) if so, whether his Ministry has taken anyi action against those companies;

(d) if so, what are the details thereof;

(e) what are the names of medicines where the companies have submitted the break-up on Form No. 4 alongwith the earlier price, increased price and percentage. increase in each case;

(f) whether his Ministry has ex-mined those break-ups; and

(g) if so, what is Government's reaction thereto?

THE MINISTER OF INDUSTRY (SHRI *J. s* VENGAL RAO): (a) As per the provisions of DPCO, 1987, companies are required to give information regarding price changes and break-up of retail prices is not required to be given ^{on} Form No. 4.

(b) to (g) Do not arise.

Production of Nendrolone Decorate

3515. SHRI PURUSHOTTAM KAKODKAR: Will the Minister of INDUSTRY be pleased to state

(a) whether Nendrolone Deconate, Isoxuprine Hcl and Diolofonancp Sodium are being produced in the country;

(b) if so, names of the producers of each alongwith the production of each during the last three year-, year-wise;

(c) names of the companies which are licensed to produced these drugs alongwith licensed capacity of each drug of each company;

(d) whether it is a fact that certain companies instead of producing the required drugs are purchasing from export houses and other category of importers and basing their formulation prices at exhorbitant prices;

(e) if so, whether his Ministry have examined the formulation prices based on these drugs;

(f) if so, what are the details thereof;

(g) whether it is a fact that the